Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

Deepak Bhatt discusses some of the most impactful trials at ACC 2026
Bhatt describes a mix of drug, device and strategy trials pointing to advances in cardiovascular science.
Cardiologist was fired for speaking out about racist texts, private jet misuse, lawsuit claims
An interventional cardiologist believes he was targeted and terminated for being outspoken about a series of incidents at his hospital.
New temporary pacing system for TAVR launches in US
New pacing system is designed to streamline TAVR cath lab workflows, cut procedural steps and increase reliability.
AI-powered EHR alerts make a world of difference for cardiologists, heart patients
AI can help care teams identify heart patients who would benefit from TAVR or another life-changing valve intervention.
FDA confirms another recall for Johnson & Johnson’s Impella heart pumps
More than 33,000 devices are affected by this recall. Customers may need to return and replace the purge cassettes included with their devices due to a risk of serious injury or death.

To unpack the large number of lat-breaking trials at the American College of Cardiology 2026 meeting, Cardiovascular Business spoke in the above video interview with Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, director of the Mount Sinai Fuster Heart Hospital, who highlighted several studies he felt had the most scientific impact. This included a mix of drug, device and strategy trials pointing to advances in cardiology. #ACC #ACC26

Deepak Bhatt discusses some of the most impactful trials at ACC 2026

Bhatt describes a mix of drug, device and strategy trials pointing to advances in cardiovascular science.

Cardiologist was fired for speaking out about racist texts, private jet misuse, lawsuit claims

An interventional cardiologist believes he was targeted and terminated for being outspoken about a series of incidents at his hospital.

The SoloPace Fusion Temporary Pacing System from Solo Pace Inc. is deigned to eliminate the need for right ventricular (RV) lead placement, which requires the added procedural step to gaining venous access. This can cut procedure time and mitigate possible complication risks. For interventional cardiologists using improvised left ventricular (LV) pacing, this system can replace ad-hoc clip assemblies, subcutaneous needles and exposed wire connections, which are known sources of inconsistent pace capture.

New temporary pacing system for TAVR launches in US

New pacing system is designed to streamline TAVR cath lab workflows, cut procedural steps and increase reliability.

AI-powered EHR alerts make a world of difference for cardiologists, heart patients

AI can help care teams identify heart patients who would benefit from TAVR or another life-changing valve intervention.

FDA confirms another recall for Johnson & Johnson’s Impella heart pumps

More than 33,000 devices are affected by this recall. Customers may need to return and replace the purge cassettes included with their devices due to a risk of serious injury or death.

Former American College of Cardiology president Hadley Wilson, MD, FACC, executive vice chair of Atrium Health's Sanger Heart and Vascular Institute, shared his thoughts on what he saw as the key studies in the above video interview with Cardiovascular Business. He covered numerous trials in more detail in the video. #ACC26 #ACC

Key clinical takeaways from ACC.26

Hadley Wilson, MD, a former American College of Cardiology president, spoke to Cardiovascular Business about several studies presented at ACC.26.

Michiel Voskuil, MD, PhD, an interventional cardiologist and professor at University Medical Center Utrecht in the Netherlands, presented his team’s data on the ACC.26 stage.

PCI before TAVR? In older CAD patients, deferral may be the best approach

Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.

Interventional cardiologist Roxana Mehran, MD, officially started her one-year term as the president of the American College of Cardiology (ACC) on the closing day of ACC.26, the group’s annual conference in New Orleans.

Interventional cardiologist Roxana Mehran elected ACC president

A prominent figure in the fields of interventional cardiology and women’s health is now leading the American College of Cardiology.